Verastem Inc
2VSA
Company Profile
Business description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Contact
117 Kendrick Street
Suite 500
NeedhamMA02494
USAT: +1 781 292-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
Finding yield on the ASX
The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
We’ve raised our fair value estimate of Exxon stock.
stocks
Disney earnings: No big surprises in solid results
Growth in areas critical to the firm’s future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 6.90 | -0.08% |
| CAC 40 | 8,200.38 | 19.21 | 0.23% |
| DAX 40 | 24,927.67 | 130.15 | 0.52% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,334.87 | 6.69 | -0.06% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,857.10 | 9.20 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |